We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.
- Authors
Kwon, Dohee; Kim, Sehui; Kim, Pil‐Jong; Go, Heounjeong; Nam, Soo Jeong; Paik, Jin Ho; Kim, Young A; Kim, Tae Min; Heo, Dae Seog; Kim, Chul Woo; Jeon, Yoon Kyung
- Abstract
Aims To investigate the clinicopathological characteristics of programmed cell death ligand 1 ( PD-L1) and programmed cell death 1 ( PD-1) expression in the tumour microenvironments of diffuse large B cell lymphoma ( DLBCL). Methods and results Tumour tissues from 126 DLBCL patients were immunostained for PD-L1 and PD-1. The expression of PD-L1 by tumour cells and/or tumour-infiltrating immune cells (mainly macrophages) was evaluated, and the number of tumour-infiltrating PD-1+ cells was assessed. PD-L1 expression in tumour cells was observed in 61.1% of DLBCLs, with a weak intensity in 29.4%, moderate intensity in 21.4% and strong intensity in 10.3% of cases. Strong PD-L1 expression in tumour cells was associated significantly with the presence of B symptoms (adjusted P = 0.005) and Epstein-Barr virus ( EBV) infection (adjusted P = 0.015), and tended to be higher in activated B cell-like immunophenotype (16.7%) than germinal centre B cell-like immunophenotype (2.5%) (adjusted P = 0.271). DLBCLs with PD-L1 expression in tumour cells/macrophages showed similar clinicopathological characteristics. The quantity of PD-1+ tumour-infiltrating lymphocytes correlated positively with the level of PD-L1 expression in tumour cells ( P = 0.042) or in tumour cells/macrophages ( P = 0.03). Increased infiltration of PD-1+ cells was associated with prolonged progression-free survival ( P = 0.005) and overall survival ( P = 0.026) in DLBCL patients treated with rituximab-cyclophosphamide, doxorubicin, vincristine, prednisone (R- CHOP), whereas PD-L1 expression had no prognostic significance. Conclusions PD-L1 and PD-1 were expressed variably in DLBCLs by tumour cells and tumour-infiltrating immune cells and might be potential therapeutic targets using PD-1/ PD-L1 blockade.
- Subjects
CELL death; LIGANDS (Biochemistry); B cells; CANCER cells; EPSTEIN-Barr virus
- Publication
Histopathology, 2016, Vol 68, Issue 7, p1079
- ISSN
0309-0167
- Publication type
Article
- DOI
10.1111/his.12882